-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Breast cancer is a major killer of women's heal.
In recent years, the number of new patients is increasing year by ye.
HER2-positive breast cancer accounts for about 20% to 30% of all breast cance.
It has the characteristics of high malignancy, rapid disease progression, easy occurrence of lymph node metastasis, and short chemotherapy remission period, which brings great challenges to clinical treatme.
Among them, brain metastasis is one of the common and devastating complications of HER2-positive breast canc.
At present, there is no standard treatment drug for the clinical treatment of brain metastases from breast canc.
For a long time, topical therapy has been the main treatment method, and patients have huge unmet clinical nee.
However, as breast cancer treatment attracts more and more attention, there are more and more pharmaceutical companies deploying in this field, and new drug research and development continu.
new ho.
On May 24, Beijing Shengnuoji Pharmaceutical Technology .
, L.
(hereinafter referred to as: Shengnuoji Pharmaceutical) announced that the company has launched SNG1005 for the treatment of "patients with brain metastases from HER2-negative breast cancer who have progressed in brain parenchyma after previous whole-brain radiotherap.
Phase II/III clinical tria.
According to reports, SNG1005 was developed by the Canadian company Angioch.
This product is a conjugate formed by combining paclitaxel molecules with chemically synthesized polypeptid.
It is a new compound entity that has not yet been marketed worldwi.
The drug can cross the blood-brain barrier and the blood-cerebrospinal fluid barri.
, into the brain to play an anti-tumor effe.
The results of the Phase II clinical trial of SNG1005 showed that the survival of patients was significantly prolong.
In addition, its Phase III clinical program has been approved by the FDA, and Shenguoji Pharmaceutical has the development and commercialization rights in Greater Chi.
Shengnuoji Pharmaceutical was approved by the State Food and Drug Administration in May 2019 and August 2019, respectively, to conduct Phase II/III clinical trials of SNG1005 breast cancer brain parenchyma metastasis and Phase III clinical trials of breast cancer leptomeningeal metastas.
It is reported that after launching a multi-center, randomized controlled, open-label clinical trial of SNG1005 comparing investigators with single-agent chemotherapy for the treatment of HER2-negative breast cancer patients with brain metastases who had progressed in brain parenchyma after prior whole-brain radiotherapy, Shengnuoji Medicine also plans to conduct SNG1005 breast cancer Phase III clinical trial of cancer meningeal metastas.
The company stated that it will speed up the above-mentioned clinical trial process and promote the urgently needed drugs to better benefit patien.
Not long ago, the online medical journal OncLive published data from the primary outcome analysis of the Phase II TUXEDO-1 trial evaluating the efficacy of Enhertu, a HER2-targeting antibody drug conjugate (ADC), in patients with HER2-positive breast cancer and active brain metastas.
and securi.
Results of the trial showed that patients with HER2-positive breast cancer with brain metastases benefited from Enhertu treatme.
The manufacturers of Enhertu are Daiichi Sankyo and AstraZene.
The drug was approved by the FDA in December 2019 for the treatment of unresectable or metastatic HER2-positive breast cancer that has received 2 or more anti-HER2 therapi.
patien.
On May 5, 2022, Enhertu was approved for an expanded indication for the treatment of patients with unresectable or metastatic HER2-positive breast canc.
According to related reports, Enhertu is an antibody-drug conjugate designed using Daiichi Sankyo's proprietary DXd ADC technolo.
It is inhibited by a humanized monoclonal antibody targeting HER2 through a tetrapeptide linker and a topoisomeraseagent connect.
This ADC can attach more cytotoxins to the antibody, which may have better tumor killing effe.
Click to enter the exhibition page
In recent years, the number of new patients is increasing year by ye.
HER2-positive breast cancer accounts for about 20% to 30% of all breast cance.
It has the characteristics of high malignancy, rapid disease progression, easy occurrence of lymph node metastasis, and short chemotherapy remission period, which brings great challenges to clinical treatme.
Among them, brain metastasis is one of the common and devastating complications of HER2-positive breast canc.
At present, there is no standard treatment drug for the clinical treatment of brain metastases from breast canc.
For a long time, topical therapy has been the main treatment method, and patients have huge unmet clinical nee.
However, as breast cancer treatment attracts more and more attention, there are more and more pharmaceutical companies deploying in this field, and new drug research and development continu.
new ho.
On May 24, Beijing Shengnuoji Pharmaceutical Technology .
, L.
(hereinafter referred to as: Shengnuoji Pharmaceutical) announced that the company has launched SNG1005 for the treatment of "patients with brain metastases from HER2-negative breast cancer who have progressed in brain parenchyma after previous whole-brain radiotherap.
Phase II/III clinical tria.
According to reports, SNG1005 was developed by the Canadian company Angioch.
This product is a conjugate formed by combining paclitaxel molecules with chemically synthesized polypeptid.
It is a new compound entity that has not yet been marketed worldwi.
The drug can cross the blood-brain barrier and the blood-cerebrospinal fluid barri.
, into the brain to play an anti-tumor effe.
The results of the Phase II clinical trial of SNG1005 showed that the survival of patients was significantly prolong.
In addition, its Phase III clinical program has been approved by the FDA, and Shenguoji Pharmaceutical has the development and commercialization rights in Greater Chi.
Shengnuoji Pharmaceutical was approved by the State Food and Drug Administration in May 2019 and August 2019, respectively, to conduct Phase II/III clinical trials of SNG1005 breast cancer brain parenchyma metastasis and Phase III clinical trials of breast cancer leptomeningeal metastas.
It is reported that after launching a multi-center, randomized controlled, open-label clinical trial of SNG1005 comparing investigators with single-agent chemotherapy for the treatment of HER2-negative breast cancer patients with brain metastases who had progressed in brain parenchyma after prior whole-brain radiotherapy, Shengnuoji Medicine also plans to conduct SNG1005 breast cancer Phase III clinical trial of cancer meningeal metastas.
The company stated that it will speed up the above-mentioned clinical trial process and promote the urgently needed drugs to better benefit patien.
Not long ago, the online medical journal OncLive published data from the primary outcome analysis of the Phase II TUXEDO-1 trial evaluating the efficacy of Enhertu, a HER2-targeting antibody drug conjugate (ADC), in patients with HER2-positive breast cancer and active brain metastas.
and securi.
Results of the trial showed that patients with HER2-positive breast cancer with brain metastases benefited from Enhertu treatme.
The manufacturers of Enhertu are Daiichi Sankyo and AstraZene.
The drug was approved by the FDA in December 2019 for the treatment of unresectable or metastatic HER2-positive breast cancer that has received 2 or more anti-HER2 therapi.
patien.
On May 5, 2022, Enhertu was approved for an expanded indication for the treatment of patients with unresectable or metastatic HER2-positive breast canc.
According to related reports, Enhertu is an antibody-drug conjugate designed using Daiichi Sankyo's proprietary DXd ADC technolo.
It is inhibited by a humanized monoclonal antibody targeting HER2 through a tetrapeptide linker and a topoisomeraseagent connect.
This ADC can attach more cytotoxins to the antibody, which may have better tumor killing effe.
Click to enter the exhibition page
